The EU Non-Hodgkin Lymphoma therapeutics market size stood at around USD XX million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of xx% during the forecast period

Lymphoma is one of the most hazardous and life threatening type of cancer, related to lymphocytes, an important type of white blood cells. Non-Hodgkins lymphomas (NHL) is a distinct group of blood cancer, which includes large variety of lymphomas, excluding Hodgkins lymphomas. Non-Hodgkins lymphoma (NHL) varies in their severity, from mild to fatal



Market Drivers

The market in Europe is likely to have substantial market growth drive throughout the forecast period owing to the enormous healthcare expenditure and advantageous health care policies. Certain factors that are driving the market growth include a rise in the prevalence of NHL, demand for innovative drugs and novel technologies, and an increase in the number of FDA approvals for NHL therapy drugs. In addition, an increase in public awareness about NHL, robust drug pipeline for the treatment of the disease, improved diagnostic techniques to detect NHL, and an increase in the prevalence of non-Hodgkin lymphoma are the factors fueling the NHL therapeutics market